Adequate cardiac function defined by the absence of the following:

a) A clinically relevant abnormality on the electrocardiogram (ECG)

b) Clinically relevant coronary artery disease or uncontrolled congestive heart failure

c) Medically uncontrolled angina pectoris

d) An implantable pacemaker or automatic implantable cardioverter-defibrillator

e) A history of risk factors for ventricular tachycardia, torsades de pointes, fainting, unexplained loss of consciousness, or convulsions

f) A history of heart failure, congestive heart failure, myocardial infarction, cardiomyopathy, uncontrolled hypokalemia, hypomagnesemia, or hypoglycemia; any evidence of conduction abnormality (eg, increased QRS complex)

g) Congenital long QT syndrome or a prolonged QTc interval mean on screening ECG

h) QTc more than 470 msec

i) History of myocardial infarction within 6 months before the first dose of study drug

j) Received sotalol within 10 days of the first dose of treatment, or received a medication known to prolong the ECG QT interval within 14 days of the first dose of treatment

k) A heart rate of <50 or >100 bpm at rest on screening ECG

l) Patients aged more than 50 years should have a cardiac stress test

m) Note: Patients with history of coronary artery disease should have a thallium stress test and be cleared to participate in the study

Normal pulmonary function, which will be established as follows:

a) Patients aged less than 40 years without medical history of pulmonary disease: no testing

b) Patients aged more than 40 years, history of smoking, or pulmonary disease: determination of FEV (minimal FEV required: 75%)